OBJECTIVE: To evaluate screening strategies based on fasting plasma glucose (FPG), clinical information, and the oral glucose tolerance test (OGTT) for detection of diabetes or other hyperglycemic states-impaired fasting glucose (IFG) and impaired glucose tolerance-meriting clinical intervention. RESEARCH DESIGN AND METHODS: We studied 8,286 African-American and white men and women without known diabetes, aged 53-75 years, who received an OGTT during the fourth exam of the Atherosclerosis Risk in Communities Study. Using a split sample technique, we estimated the diagnostic properties of various clinical detection rules derived from logistic regression modeling. Screening strategies utilizing FPG, these detection rules, and/or the OGTT were then compared in terms of both the fraction of hyperglycemia cases detected and the sample fraction receiving different screening tests and identified as screen positive. RESULTS: Screening based on the IFG cut point (> or =6.1 mmol/l), followed by a clinical detection rule for those below this value, detected 86.3% of diabetic case subjects and 66.0% of all hyperglycemia cases, identifying 42% of the sample as screen positive. Applying an OGTT for those positive by the rule provides diagnostic labeling and reduces the fraction that is screen positive to 29%. Another strategy, to apply an OGTT to those with an FPG cut point between 5.6 and 6.1 mmol/l, also identifies 29% of the sample as screen positive, although it detects slightly fewer hyperglycemia cases. CONCLUSIONS: Screening strategies based on FPG, complemented by clinical detection rules and/or an OGTT, are effective and practical in the detection of hyperglycemic states meriting clinical intervention.
OBJECTIVE: To evaluate screening strategies based on fasting plasma glucose (FPG), clinical information, and the oral glucose tolerance test (OGTT) for detection of diabetes or other hyperglycemic states-impaired fasting glucose (IFG) and impaired glucose tolerance-meriting clinical intervention. RESEARCH DESIGN AND METHODS: We studied 8,286 African-American and white men and women without known diabetes, aged 53-75 years, who received an OGTT during the fourth exam of the Atherosclerosis Risk in Communities Study. Using a split sample technique, we estimated the diagnostic properties of various clinical detection rules derived from logistic regression modeling. Screening strategies utilizing FPG, these detection rules, and/or the OGTT were then compared in terms of both the fraction of hyperglycemia cases detected and the sample fraction receiving different screening tests and identified as screen positive. RESULTS: Screening based on the IFG cut point (> or =6.1 mmol/l), followed by a clinical detection rule for those below this value, detected 86.3% of diabetic case subjects and 66.0% of all hyperglycemia cases, identifying 42% of the sample as screen positive. Applying an OGTT for those positive by the rule provides diagnostic labeling and reduces the fraction that is screen positive to 29%. Another strategy, to apply an OGTT to those with an FPG cut point between 5.6 and 6.1 mmol/l, also identifies 29% of the sample as screen positive, although it detects slightly fewer hyperglycemia cases. CONCLUSIONS: Screening strategies based on FPG, complemented by clinical detection rules and/or an OGTT, are effective and practical in the detection of hyperglycemic states meriting clinical intervention.
Authors: Mercedes R Carnethon; Mary L Biggs; Joshua Barzilay; Lewis H Kuller; Dariush Mozaffarian; Kenneth Mukamal; Nicholas L Smith; David Siscovick Journal: Am J Med Date: 2010-06 Impact factor: 4.965
Authors: Manjusha Kulkarni; Randi E Foraker; Ann M McNeill; Cynthia Girman; Sherita H Golden; Wayne D Rosamond; Bruce Duncan; Maria Ines Schmidt; Jaakko Tuomilehto Journal: Diabetes Obes Metab Date: 2017-05-22 Impact factor: 6.577
Authors: C M Ballantyne; R C Hoogeveen; A M McNeill; G Heiss; M I Schmidt; B B Duncan; J S Pankow Journal: Int J Obes (Lond) Date: 2008-05 Impact factor: 5.095
Authors: Eman A El Bassuoni; David C Ziemer; Paul Kolm; Mary K Rhee; Viola Vaccarino; Circe W Tsui; Jack M Kaufman; G Eileen Osinski; David D Koch; K M Venkat Narayan; William S Weintraub; Lawrence S Phillips Journal: Prim Care Diabetes Date: 2008-06-11 Impact factor: 2.459
Authors: L S Phillips; D C Ziemer; P Kolm; W S Weintraub; V Vaccarino; M K Rhee; R Chatterjee; K M V Narayan; D D Koch Journal: Diabetologia Date: 2009-06-26 Impact factor: 10.122
Authors: Timo E Saaristo; Noël C Barengo; Eeva Korpi-Hyövälti; Heikki Oksa; Hannu Puolijoki; Juha T Saltevo; Mauno Vanhala; Jouko Sundvall; Liisa Saarikoski; Markku Peltonen; Jaakko Tuomilehto Journal: BMC Public Health Date: 2008-12-29 Impact factor: 3.295